Skip to main content
. 2021 Sep 21;12(10):857. doi: 10.1038/s41419-021-04162-0

Fig. 6. Nobiletin enhanced the sensitivity of CRPC to enzalutamide.

Fig. 6

A CCK8 assay was performed in 22Rv1 cells treated with enzalutamide in the presence or absence nobiletin for 48 h. Mean ± SD (n = 3). B Colony formation assay of 22Rv1 cells exposed to enzalutamide with or without nobiletin for 2 weeks. C Quantitative data of B are shown. Mean ± SD (n = 3). D Xenograft images are shown. 22Rv1 xenografts treated with drug solvent, 40 mg/kg/2d (i.p.) of nobiletin, 25 mg/kg/2d (p.o.) of enzalutamide and combination of nobiletin and enzalutamide for 25 days. E Tumor sizes are shown. Mean ± SD (n = 10). F Tumor weight are shown. Mean ± SD (n = 10). G Body weight of nude mice are shown. Mean ± SD (n = 10). H IHC assay of AR-V7 and Ki67. Representative images in per group are shown at 200*. I Quantitative data of H are shown. Mean ± SD (n = 3). J H&E staining assay was performed in liver and kidney tissue of nude mice. Representative images in per group are shown at 200*.